The HDAC6 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population for disruption of the HDAC6 gene in the HAP1 human cell line. This model facilitates loss-of-function studies of the cytoplasmic deacetylase HDAC6, bypassing the need for single-cell subcloning while retaining genetic diversity for robust functional analyses.
The HAP1 line is a near-haploid human cell line derived from KBM-7 CML cells, with adherent fibroblast-like morphology and a simplified karyotype that enhances genetic tractability. It is widely used for knockout studies due to its haploid nature, which reduces genetic redundancy and simplifies genotype-phenotype correlations, making it an ideal platform for targeted gene disruption.
HDAC6 is a cytoplasmic deacetylase that targets non-histone proteins, notably ??-tubulin, Hsp90, and cortactin, thereby regulating microtubule stability, protein folding, and cell migration. Its activity is modulated by upstream inputs including EGFR, Aurora A kinase, GSK-3??, and reactive oxygen species. HDAC6 mediates the aggresome-autophagy pathway by interacting with p62/SQSTM1 and dynein, facilitating the perinuclear transport of ubiquitinated aggregates for degradation. It also influences signaling cascades through deacetylation of ??-catenin and peroxiredoxin-1, linking it to cell proliferation and antioxidant responses. Through these interactions, HDAC6 integrates stress signals, cytoskeletal dynamics, and proteotoxic stress management.
In the HAP1 CML background, HDAC6 knockout enables precise dissection of its contributions to cancer cell biology, particularly in drug resistance mechanisms. HDAC6 sustains survival of hematological malignancies by promoting aggresome clearance of misfolded proteins, a process that can be targeted by proteasome inhibitors. Its deacetylation of ??-tubulin affects cell motility, relevant to metastasis, while Hsp90 deacetylation modulates client protein stability, impacting oncogenic signaling. The near-haploid nature of HAP1 ensures a clean genetic background for such studies, allowing robust phenotypic comparisons and the identification of pathway dependencies.
Key applications include studying autophagy and aggresome formation, microtubule dynamics, and screening for HDAC6 inhibitors like tubastatin A. Compatible assays encompass western blot for acetylated ??-tubulin and Hsp90, immunofluorescence for microtubule organization, migration/invasion assays, and flow cytometry for LC3. Aggresome formation can be assessed using proteasome inhibitors, while RT-qPCR and drug sensitivity assays provide functional readouts. For further information, please contact Ascent Research.
